Please provide your email address to receive an email when new articles are posted on . Intravitreal steroids have been widely used in the treatment of various ocular pathologies including macular ...
A sustained-release dexamethasone device implanted during pars plana vitrectomy may be effective in pre-emptively reducing macular edema in patients with various underlying ocular diseases at risk for ...
A total of 102 eyes of 85 subjects who received Ozurdex for DME were evaluated. Twenty-three eyes, which had <1 year follow-up, were excluded. Finally, 79 eyes of 62 subjects were included in this ...
OZURDEX (dexamethasone) intravitreal implant by Allergan Allergan's Ozurdex (dexamethasone intravitreal implant) has been approved by the FDA for the treatment of macular edema following branch ...
Used in combination with antivascular endothelial growth factor (anti-VEGF) therapy, dexamethasone implants (0.7 mg Ozurdex, Allergan) may help some patients with neovascular age-related macular ...
It is with great interest that we read another case of Ozurdex implant malpositioned in the crystalline lens, as reported by Chalioulias and Muqit. 1 Although the complication is rare, with increasing ...
Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a real-world observational study titled ‘A Two ...
Eye drugs are a longtime staple of Irvine? Allergan Inc., and the company? arsenal is about to pick up a new weapon in the coming weeks. The Food and Drug Administration has cleared Allergan? Ozurdex ...
NEW YORK, July 28 (Reuters) - Allergan Inc on Wednesday said its drug Ozurdex has become the first drug in Europe approved to treat a eyesight-endangering condition in which fluid builds up in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback